1. Clinical Overview of Adipotide
Molecule:
Adipotide is a synthetic peptidomimetic homing molecule consisting of:
- A prohibitin-targeting domain
- A pro-apoptotic motif (KLAKLAK)
Primary innovation: Adipotide selectively binds to blood vessels feeding white adipose tissue, causing apoptosis of those vessels, leading to:
- Reduced blood supply to fat cells
- Adipocyte shrinkage
- Rapid fat loss
Classification:
- Adipose-targeted pro-apoptotic peptide
- Angiogenesis-inhibiting molecule
- Obesity research drug
2. Mechanisms of Action
Adipotide works by selectively destroying the blood supply of white fat tissue.
2.1 Targeting Prohibitin on Adipose Vascular Endothelium
Adipocyte-associated vasculature expresses elevated prohibitin, a surface protein. Adipotide binds to prohibitin with high specificity.
2.2 Internalization & Mitochondrial Disruption
After binding:
- The peptide is internalized into endothelial cells
- The KLAKLAK segment disrupts mitochondrial membranes
- Endothelial cells undergo apoptosis
2.3 Adipocyte Starvation → Fat Cell Reduction
Destruction of blood vessels:
- Cuts nutrient supply
- Causes adipocyte apoptosis
- Leads to rapid reduction in white fat mass
This is unlike GLP-1 agonists (appetite suppression), AOD-9604 (lipolytic signaling), or SLU-PP-332 (mitochondrial thermogenesis). Adipotide directly eliminates fat cells.
2.4 Rapid Weight-Loss Mechanism
2.5 Renal Toxicity Mechanism (Important)
- Elevated creatinine
- BUN rise
- Electrolyte imbalance
- Reversible tubular toxicity
3. Evidence-Supported (Investigational) Applications
3.1 Severe Obesity (Research Only)
Most effective in:
- High visceral fat burden
- GLP-1-resistant obesity
- Insulin-resistant phenotypes
Not for cosmetic fat loss.
3.2 Metabolic Syndrome (Research)
Potential improvements noted in:
- Fasting glucose
- Triglycerides
- Waist circumference
- Liver fat infiltration
3.3 GLP-1 Non-Responders (Investigational Use)
Adipotide may assist patients who:
- Plateau on semaglutide or tirzepatide
- Fail to achieve appetite suppression
- Have major visceral fat stores
3.4 Specialized Obesity Cases
Potential future applications (research only):
- PCOS with severe insulin resistance
- Lipodystrophy
- Pre-bariatric weight reduction strategy
- Obesity-related orthopedic load reduction
4. Administration Routes & Clinical Protocols
4.1 Subcutaneous or Intramuscular Injection (Research Context)
- 0.5–1 mg/kg SC or IM daily
- For 28 days, then off-cycle
Extrapolated human dosing in research settings tends to be far lower to prevent renal toxicity.
4.2 Conservative Human-Derived Research Dosing
(used experimentally with intensive renal monitoring)
- 0.5–5 mg SC daily, depending on weight
- 5 days on → 2 days off schedule
- Maximum: 4 weeks per cycle
4.3 Slow-Titration Kidney-Safety Protocol
Week 2: 2 mg SC daily
Weeks 3–4: 3–5 mg SC daily
Never exceed 5 mg/day in research settings.
4.4 Cycling
- 1 cycle = 4 weeks
- Off-cycle = minimum 4–8 weeks
- Kidney labs must normalize before next cycle
4.5 Hydration Requirements
- 2.5–3.5 L water daily
- Avoid NSAIDs
- Limit creatine, high-protein diets
5. Combination Therapy (Peptide Protocol Portal Synergy — Research Only)
Safe adjuncts include metabolic peptides that do not burden kidneys, such as:
5.1 Adipotide + SLU-PP-332
Synergy via:
- Fat-cell apoptosis (Adipotide)
- Thermogenesis and mitochondrial activation (SLU-PP-332)
5.2 Adipotide + AOD-9604
Targets:
- Apoptosis-induced fat loss
- GH-fragment lipolysis pathways
5.3 Adipotide + Tesofensine
Addresses:
- Reward-driven eating
- Caloric intake regulation
5.4 Adipotide + MOTS-c
Improves:
- Mitochondrial resilience
- Cellular energy
- Insulin sensitivity
Supports metabolism during rapid fat turnover.
5.5 Adipotide + SS-31
May protect against mitochondrial oxidative stress during apoptosis-mediated fat clearance.
6. Clinical Decision Trees
Decision Tree 1 — Is Adipotide Appropriate (Research Context Only)?
Severe visceral-fat obesity? → POSSIBLE
Non-responder to GLP-1 or tirzepatide? → POSSIBLE
Willing for intensive kidney monitoring? → REQUIRED
History of kidney disease? → DO NOT USE
Cosmetic weight loss? → NOT APPROPRIATE
Decision Tree 2 — Safety & Titration
Creatinine elevated? → HOLD or STOP
Symptoms of dehydration? → INCREASE HYDRATION + HOLD DOSE
GI fatigue or flu-like symptoms? → REDUCE DOSE
Cycle complete? → 4–8 week washout
7. Integrated Treatment Archetypes (Investigational)
Archetype A — Severe Obesity / GLP-1 Failure
Systemic:
- Adipotide (low-dose research dosing)
- SLU-PP-332
- Tesofensine
- MOTS-c
Archetype B — Visceral Obesity with Insulin Resistance
Systemic:
- Adipotide
- AOD-9604
- NAD+
- Low-insulin diet
Archetype C — Pre-Bariatric Intervention (Research)
Systemic:
- Adipotide
- Low-dose semaglutide or tirzepatide
- SLU-PP-332
8. Expected Research Timelines
9. Contraindications & Precautions (Critical)
Absolute Contraindications
- Kidney disease
- History of acute kidney injury
- Severe dehydration
- Pregnancy
- Breastfeeding
- Active malignancy (due to apoptosis involvement)
Relative Contraindications
- Hypertension
- Liver disease
- Taking nephrotoxic medications
- Prolonged fasting states
10. Adverse Effects
Most common:
- Nausea
- Fatigue
- Injection site soreness
- Thirst
Kidney-related (dose-dependent):
- Elevated creatinine
- Increased BUN
- Electrolyte imbalance
- Reduced GFR
Rare:
- Acute kidney injury
- Abdominal cramping
- Hypotension due to dehydration
11. Monitoring Guidelines (Mandatory)
Baseline Required
- Comprehensive metabolic panel
- Creatinine
- BUN
- GFR
- Electrolytes
- Hydration status
Weekly During Cycle
- Creatinine
- BUN
- Hydration assessment
Post-cycle (2–4 weeks)
- Repeat kidney labs
Legal Disclaimer
The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.
Adipotide (FTPP / Prohibitin-Targeting Peptide), and other peptides referenced herein are not FDA-approved drugs. Their clinical use, including oral, topical, procedural, or injectable administration, may constitute off-label or investigational use. Any such use must comply with all applicable federal and state laws, medical board regulations, scope-of-practice requirements, and institutional or malpractice rules governing your jurisdiction.
Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented. Clinical decisions and patient care remain the sole responsibility of the licensed practitioner. Practitioners must exercise independent clinical judgment and assess each patient's individual medical needs, risks, comorbidities, and contraindications prior to implementing any protocol.
Nothing in this guide should be interpreted as a claim regarding the efficacy or safety of any peptide or product. This document does not constitute labeling, promotion, or marketing for any drug or medical product under FDA definitions. Any compounding, reconstitution, or administration of peptides must follow appropriate sterile technique and must only be performed by individuals lawfully authorized to handle such materials.
By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.
Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.
References — Adipotide (FTPP) Clinical Reference Guide
Provider Access Required
Create a provider account to read the full clinical guide for Adipotide (FTPP / Prohibitin-Targeting Peptide).